Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progressive facial atrophy: a rare case of Parry-Romberg syndrome in an active-duty soldier.

BMJ military health·2025
Same author

Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.

ESMO open·2022
Same author

Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer.

Breast cancer research and treatment·2022
Same author

2021 Canadian Surgery Forum: Virtual, online Sept. 21-24, 2021.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Projecting effects of land use change on human well-being through changes in ecosystem services.

Ecological modelling·2021
Same author

Approach to screening for Familial Adenomatous Polyposis (FAP) in a cohort of 226 patients with Desmoid-type Fibromatosis (DF): experience of a specialist center in the UK.

Familial cancer·2021
Same journal

Predicting Post-Radiotherapy Lymphocyte Recovery for Individualized Risk Stratification in Locally Advanced Esophageal Squamous Cell Carcinoma.

Current oncology (Toronto, Ont.)·2026
Same journal

From Adjunct to Essential: Integrating Supportive Care into Oncology.

Current oncology (Toronto, Ont.)·2026
Same journal

Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice.

Current oncology (Toronto, Ont.)·2026
Same journal

The Route of Administration Determines the Efficacy of Zinc in Preventing Radiation-Induced Oral Mucositis: A Systematic Review and Meta-Analysis.

Current oncology (Toronto, Ont.)·2026
Same journal

Mechanisms of Progression and Challenges for Intervention in the Natural History of Early Prostate Cancer: A Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same journal

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Current oncology (Toronto, Ont.)·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K

Update on systemic therapy for advanced soft-tissue sarcoma.

A Smrke1, Y Wang1, C Simmons1

  • 1BC Cancer-Vancouver Centre, Vancouver, BC.

Current Oncology (Toronto, Ont.)
|March 17, 2020
PubMed
Summary
This summary is machine-generated.

Outcomes for advanced soft-tissue sarcoma (STS) have improved, but first-line treatments remain challenging. Novel therapies and subtype-specific trials are crucial for enhancing patient survival in this rare cancer.

Keywords:
Soft-tissue sarcomaadvancedanthracyclinessystemic therapy

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.1K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.1K

Related Experiment Videos

Last Updated: Dec 26, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.8K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.1K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.1K

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Soft-tissue sarcoma (STS) is a rare and heterogeneous group of mesenchymal neoplasms.
  • Advanced STS includes unresectable or metastatic disease, necessitating effective systemic therapies.
  • Understanding treatment advancements for advanced STS is critical for improving patient outcomes.

Purpose of the Study:

  • To evaluate trends in patient outcomes for advanced soft-tissue sarcoma over time.
  • To assess the current evidence supporting systemic therapy options for advanced STS.
  • To identify challenges and future directions in managing advanced STS.

Main Methods:

  • A scoping review was conducted to analyze contemporary evidence for systemic treatment of advanced STS in adults.
  • Inclusion criteria encompassed Phase I, II, and III studies of systemic therapy for advanced STS published in English.
  • Seventy-seven studies were initially screened, with sixty-two ultimately meeting the inclusion criteria.

Main Results:

  • The number of clinical trials for advanced STS has risen significantly over the past 30 years.
  • While median overall survival has increased, first-line therapy improvements via dose intensification or doublet chemotherapy have not been successful.
  • Despite challenges posed by STS heterogeneity, increasing numbers of novel agents show promise for isolated benefits in progression-free or overall survival.

Conclusions:

  • Anthracycline-based chemotherapy remains the standard first-line treatment for advanced STS.
  • Selecting optimal therapy beyond first-line anthracyclines presents a significant challenge.
  • Future improvements in advanced STS outcomes may come from novel systemic therapies, molecular diagnostics, subtype-specific trials, and real-world data analysis.